We are pleased that 6 Dimensions Capital has announced the final close of its inaugural US dollar fund and RMB fund at US $533 million and RMB2.06 billion respectively, both exceeded the original US $450 million and RMB 1.5 billion target.

Formed through a merger between Frontline BioVentures and WuXi Healthcare Ventures in May 2017, 6 Dimensions Capital has established itself firmly as one of the largest healthcare focused investment firms with coverage across China and the U.S. Investors in the USD fund include some of the prominent industry leaders along with endowments, foundations, and sovereign wealth funds, and investors in the RMB fund include some of the top-tier fund-of-funds, mainstream insurance companies, and industrial leading players.

Dr. Ge Li, founding partner and chairman of 6 Dimensions Capital, noted, “I am very pleased to see the enthusiasm from the investment community that embraces healthcare opportunities as much as we do. I believe this significant amount of fresh capital will empower the 6 Dimensions Capital team to execute our highly differentiated investment strategies and solidify our leadership in the healthcare venture investment.”